Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,077.98 -38.19 (-0.75%) Dow
38,068.61 -317.48 (-0.83%) Nasdaq
15,840.64 -142.45 (-0.89%) Bitcoin USD
62,955.66 -677.18 (-1.06%) CMC Crypto 200
1,300.32 -38.74 (-2.89%)
Addex Therapeutics Ltd (ADXN.SW)
| Previous close | 0.0630 |
| Open | 0.0600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0600 - 0.0700 |
| 52-week range | 0.0362 - 0.2600 |
| Volume | |
| Avg. volume | 1,107,040 |
| Market cap | 7.824M |
| Beta (5Y monthly) | 1.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings date | 18 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAddex Provides Update on ADX71149 Phase 2 Epilepsy Study
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam. The Pha
- GlobeNewswire
Addex to Present at the Swiss Biotech Day 2024
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland. In his live presentation, scheduled for 13:45 – 14:00 CEST, on April 23, 2024, in the Samarkand room on the third floor, Mr. Dyer will provide a corporat
- GlobeNewswire
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 18, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation
